Literature DB >> 14702270

An open-label trial of riluzole in patients with treatment-resistant major depression.

Carlos A Zarate1, Jennifer L Payne, Jorge Quiroz, Jonathan Sporn, Kirk K Denicoff, David Luckenbaugh, Dennis S Charney, Husseini K Manji.   

Abstract

OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression.
METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks.
RESULTS: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers.
CONCLUSIONS: Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702270     DOI: 10.1176/appi.ajp.161.1.171

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  107 in total

1.  Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.

Authors:  Jaskaran Singh; Carlos A Zarate; Andrew D Krystal
Journal:  Psychopharmacology (Berl)       Date:  2004-01-14       Impact factor: 4.530

Review 2.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 3.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 4.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 5.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

6.  Candidate hippocampal biomarkers of susceptibility and resilience to stress in a rat model of depression.

Authors:  Kim Henningsen; Johan Palmfeldt; Sofie Christiansen; Isabel Baiges; Steffen Bak; Ole Nørregaard Jensen; Niels Gregersen; Ove Wiborg
Journal:  Mol Cell Proteomics       Date:  2012-02-06       Impact factor: 5.911

7.  Patterned expression of ion channel genes in mouse dorsal raphe nucleus determined with the Allen Mouse Brain Atlas.

Authors:  J Scott Templin; Sun Jung Bang; Mariano Soiza-Reilly; Charles B Berde; Kathryn G Commons
Journal:  Brain Res       Date:  2012-04-04       Impact factor: 3.252

8.  Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress.

Authors:  Jian-Xin Chen; Li-Hua Yao; Bi-Bo Xu; Kun Qian; Hui-Ling Wang; Zhong-Chun Liu; Xiao-Ping Wang; Gao-Hua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

9.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 10.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.